WuXi Biologics Expanding Manufacturing Capacity in Massachusetts to Meet Growing Demand

he added capacity will further enhance WuXi Biologics’ commercial manufacturing capabilities in the U.S. The site is expected to employ 250 people...

January 08, 2024 | Monday | News
SanReno Therapeutics Acquired by Novartis in Key Move for Kidney Disease Therapeutics

Novartis to acquire SanReno's product pipeline and capabilities, including the exclusive rights for Greater Chinaand Singapore Transaction reflects the&...

January 05, 2024 | Friday | News
Junshi Biosciences Gets Approval for Toripalimab as Perioperative Treatment in Resectable NSCLC

Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company ded...

January 03, 2024 | Wednesday | News
Innovent, Xuanzhu Collaborate on Clinical Trial for Advanced Solid Tumors in China

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality me...

December 28, 2023 | Thursday | News
Elpiscience, Astellas Partner on Bispecific Macrophage Engager

The two companies will collaboratively conduct early-stage research for these two programs. Elpiscience will also grant Astellas the right to add up to two...

December 28, 2023 | Thursday | News
PharmaBlock Opens HPAPI GMP Facility at Zhejiang Manufacturing Site

The new HPAPI GMP facility enables PharmaBlock to offer process R&D and kilo-scale production of HPAPIs and ADC toxins. It spans an area of 1000 m...

December 27, 2023 | Wednesday | News
Everest Medicines' Nefecon® NDA Accepted in Taiwan for Adult Primary IgA Nephropathy

Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization ...

December 27, 2023 | Wednesday | News
Takeda's LIVTENCITY® Approved in China for Post-Transplant CMV Treatment

Approval Based on Phase 3 TAK-620-303 SOLSTICE Study Demonstrating Maribavir Was Superior to Conventional Therapies at Week 8, for Primary Endpoint1-...

December 22, 2023 | Friday | News
Inventiva Enrolls First Patient in China for NATiV3 Trial and Updates Clinical Development Program

The first patient was randomized in China in the NATiV3 Phase III clinical trial, triggering a milestone payment of $3 million from CTTQ to Inventiva.&nb...

December 21, 2023 | Thursday | News
First patient in China has been dosed in the YOLT-201 clinical trial for the treatment of Hereditary ATTR-CM

The study by YolTech is a single-arm, open-label, dose-escalation clinical trial (Clinicaltrials.gov: NCT06082050). This trial's primary objectives are to ...

December 18, 2023 | Monday | News
Innovent Secures New Reimbursement Milestones for TYVYT® and BYVASDA® in China

In the updated NDRL, TYVYT® expands its coverage to the seventh new indication for the treatment of patients with epidermal growth factor receptor (EGF...

December 13, 2023 | Wednesday | News
Mabwell's Novel Nectin-4 ADC Granted CDE Approval for Phase III Trial

9MW2821 is a novel Nectin-4 targeting ADC developed independently by Mabwell, marking the first of its kind among the products developed in China with the ...

December 11, 2023 | Monday | News
Merck Boosts Oncology Portfolio with Commercialization Agreement for Phase III Asset Pimicotinib from Abbisko

Pimicotinib (ABSK021) is currently in a global Phase III study in tenosynovial giant cell tumor (TGCT) Merck to receive an exclusive commercial license ...

December 05, 2023 | Tuesday | News
Everest Medicines' Zetomipzomib IND Accepted in China

-- Everest plans to contribute to the ongoing global Phase 2b PALIZADE trial of zetomipzomib in active lupus nephritis –  -...

December 04, 2023 | Monday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close